TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05533229

Intervention type: DRUG
Intervention: Fentanyl
Description: The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.

Intervention type: DRUG
Intervention: Morphine
Description: The trial aims to study the quality of anesthesia, perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
Study: NCT06427135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Description: Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
Study: NCT04927169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT06133504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Multimodal Therapy
Description: Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Multimodal Therapy
Description: Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
Study: NCT06020872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy program
Description: Health literacy program was the health education related to healthy plate.
Study: NCT05742308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
Study: NCT04387240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin / Artesunate
Description: testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo or sham drug will be given to the second arm
Study: NCT06356480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1% Acetic acid dressing
Description: 1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
Study: NCT05453149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Physical Activity and Behavioural Change Intervention
Description: Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies.
Study: NCT05825157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioBridge
Description: Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBridge
Description: Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
Study: NCT05884164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic erector spinae plane block
Description: After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral plane block
Description: After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
Study: NCT05032924

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPR group with ESWT
Description: extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPR group without ESWT
Description: PRP or HA injection only

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: HA group with ESWT
Description: extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: HA group without ESWT
Description: PRP or HA injection only
Study: NCT06110637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hard shoes runners evaluation
Description: The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft shoes runners evaluation
Description: The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated.
Study: NCT04708457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VV-ECMO
Description: Early use of VV-ECMO in SARI patients.
Study: NCT05881070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-health self management
Description: Mobile-health self management
Study: NCT05686044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buntanetap/Posiphen
Description: HPMC (vegetarian source) capsule shells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buntanetap/Posiphen
Description: HPMC (vegetarian source) capsule shells
Study: NCT04551638

Intervention type: OTHER
Intervention: Psychological assessment with the Repertory Grid Technique
Description: The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
Study: NCT04835493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
Study: NCT06339879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Whole Grain, Low Sugar
Description: 6 servings of whole grain and \<13% energy from added sugars.
Study: NCT05686044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buntanetap/Posiphen
Description: HPMC (vegetarian source) capsule shells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HPMC (vegetarian source) capsule shells
Study: NCT05711082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Précurseur de la dopamine
Description: In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antagoniste D2
Description: In the second condition, volunteers will receive Sulpiride 800 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In the third condition, volunteers will receive placebo
Study: NCT05041608

Intervention type: PROCEDURE
Intervention: Endoscopic Surgery
Description: These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
Study: NCT05048576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Reinforcement
Description: Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Reinforcement
Description: Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: No recordings will be played during this condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participant's can choose their own music to play during this condition.
Study: NCT04750616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: Niacinamide 3 grams on the day of surgery and post-surgical days one and two

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo on the day of surgery and post-surgical days one and two
Study: NCT05203900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula with Human Milk Oligosaccharide
Description: Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula without Human Milk Oligosaccharide
Description: Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
Study: NCT05148195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envofolimab
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envofolimab
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envofolimab
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envofolimab
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD0801
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD0801
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD0801
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: 400mg/m2，Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouridine
Description: 2400 mg/m2，Q2W
Study: NCT06125080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone (30 mg/m2, days 1-5, every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: Tirelizumab（200mg, day1, every 3 weeks）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab(7.5mg/kg, day1, every 3 weeks)
Study: NCT05155891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP Procedure
Description: The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
Study: NCT05960721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 15mg
Description: QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15mg
Description: QD
Study: NCT06339879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Whole Grain, Low Sugar
Description: 3 servings of whole grain and \<13% energy from added sugars.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Whole Grain, High Sugar
Description: 6 servings of whole grain and \>13% energy from added sugars.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Whole Grain, High Sugar
Description: 3 servings of whole grain and \>13% energy from added sugars.
Study: NCT05532410

Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Camera
Description: The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
Study: NCT06260280

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Nuclear Magnetic Resonance
Description: Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
Study: NCT05054725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet
Study: NCT05269394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: Administered intravenously in a blinded fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lecanemab
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (E2814)
Description: Placebo administered intravenously in a blinded fashion.
Study: NCT06095765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG Oral Tablet
Description: Oral intake of 0.5 mg colchicine once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of matching placebo once daily
Study: NCT05960721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5mg
Description: B.I.D
Study: NCT04211675

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Natural Killer Cells
Description: NK cells dose 1x 108 cells/ kg on day 8 of each cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 50mg/m2/dose IV daily on Days 1-5

Intervention type: DRUG
Group type: OTHER
Intervention: Dinutuximab
Description: Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5

Intervention type: DRUG
Group type: OTHER
Intervention: Sargramostim
Description: Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
Study: NCT05194423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Replacement System via jugular vein
Description: To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
Study: NCT06533761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eganelisib
Description: eganelisib will be administered as monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eganelisib in combination with cytarabine
Description: eganelisib will be administered in combination with cytarabine
Study: NCT06421103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
Study: NCT05722444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nighttime Feminine Product
Description: During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak
Study: NCT06335745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PediCARE Intervention
Description: A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
Study: NCT05867979

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes
Description: The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.